Literature DB >> 16424494

Medical treatment of early breast cancer. III: chemotherapy.

Ian Smith1, Susan Chua.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16424494      PMCID： PMC1336770          DOI： 10.1136/bmj.332.7534.161

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

Authors:  A Goldhirsch; J H Glick; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2005-09-07       Impact factor: 32.976

2.  Adjuvant docetaxel for node-positive breast cancer.

Authors:  Miguel Martin; Tadeusz Pienkowski; John Mackey; Marek Pawlicki; Jean-Paul Guastalla; Charles Weaver; Eva Tomiak; Taher Al-Tweigeri; Linnea Chap; Eva Juhos; Raymond Guevin; Anthony Howell; Tommy Fornander; John Hainsworth; Robert Coleman; Jeferson Vinholes; Manuel Modiano; Tamas Pinter; Shou C Tang; Bruce Colwell; Catherine Prady; Louise Provencher; David Walde; Alvaro Rodriguez-Lescure; Judith Hugh; Camille Loret; Matthieu Rupin; Sandra Blitz; Philip Jacobs; Michael Murawsky; Alessandro Riva; Charles Vogel
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

3.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Authors:  Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-02-13       Impact factor: 44.544

4.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authors:  I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544
  5 in total
  3 in total

1.  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

Authors:  George Fountzilas; Christos Valavanis; Vassiliki Kotoula; Anastasia G Eleftheraki; Konstantine T Kalogeras; Olympia Tzaida; Anna Batistatou; Ralf Kronenwett; Ralph M Wirtz; Mattheos Bobos; Eleni Timotheadou; Nikolaos Soupos; George Pentheroudakis; Helen Gogas; Dimitrios Vlachodimitropoulos; Genovefa Polychronidou; Gerasimos Aravantinos; Angelos Koutras; Christos Christodoulou; Dimitrios Pectasides; Petroula Arapantoni
Journal:  J Transl Med       Date:  2012-01-12       Impact factor: 5.531

2.  Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.

Authors:  George Fountzilas; Urania Dafni; Mattheos Bobos; Vassiliki Kotoula; Anna Batistatou; Ioannis Xanthakis; Christos Papadimitriou; Ioannis Kostopoulos; Triantafillia Koletsa; Eleftheria Tsolaki; Despina Televantou; Eleni Timotheadou; Angelos Koutras; George Klouvas; Epaminontas Samantas; Nikolaos Pisanidis; Charisios Karanikiotis; Ioanna Sfakianaki; Nicholas Pavlidis; Helen Gogas; Helena Linardou; Konstantine T Kalogeras; Dimitrios Pectasides; Meletios A Dimopoulos
Journal:  BMC Cancer       Date:  2013-03-28       Impact factor: 4.430

3.  Identification of a 9-gene prognostic signature for breast cancer.

Authors:  Zelin Tian; Jianing Tang; Xing Liao; Qian Yang; Yumin Wu; Gaosong Wu
Journal:  Cancer Med       Date:  2020-10-14       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.